With a legacy stretching back to 1983, Advarra is the premier provider of institutional review board (IRB), institutional biosafety committee (IBC) and research quality and compliance consulting services in North America. Fully accredited by AAHRPP, Advarra serves the world’s leading pharmaceutical, biotechnology, medical device and contract research organizations, as well as academic medical centers, hospital systems, investigative site networks and therapeutic research consortia.
To address the increasingly complex needs associated with research, Advarra leverages exceptional client service, innovative technology and robust global regulatory expertise. Advarra also provides deep experience across all major therapeutic areas and continues to pioneer highly specialized review services for areas such as oncology and neurology.
Above all, Advarra provides integrated compliance services with unprecedented clarity, helping you navigate regulatory requirements more confidently.
Apply the highest standards of ethics and research compliance for the advancement of human health.
Be the global partner of choice for research compliance services and set the standard for ethical review, efficiency and thought leadership across the entire research continuum.
In 2017, two of the research industry’s most respected IRBs — Chesapeake IRB and Schulman IRB — merged to form Advarra. The combined organization leverages mutual strengths in technology, regulatory expertise and customer service to address the increasingly complex needs associated with research.
Chesapeake IRB has provided independent IRB submission and review services to research sponsors, CROs, investigators and academic medical centers and hospital systems since 1993. The paperless, cloud-based submission and review platform originally developed by Chesapeake IRB, the Center for IRB Intelligence or “CIRBI,” has been further enhanced by Advarra and continues to lead the field in setting the standard in quality, easy document accessibility and review turnaround time.
Founded in 1983, Schulman IRB has long been a leader in the protection of human research participants. By offering thorough, timely IRB review services — including dedicated review capabilities for all phases of research across all therapeutic areas — Schulman IRB became a preferred provider for many of the world’s largest clinical trial sponsors, CROs, investigators and institutions. Schulman also pioneered specialized, expert therapeutic review services such as Central Oncology Review (COR) and Central Neurology Review (CNR).
Advarra is focused on increasing the quality and efficiency of IRB, IBC and compliance consulting services.